ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

Tune in to the ASCO in Action podcast series for analysis and commentary on cancer policy and practice issues. The podcast is available through iTunes or Google Play.

Showing results for NIH/NCI

May 10, 2022

The Provider Relief Fund (PRF) Request to Report Late Due to Extenuating Circumstances process is for providers who were required to report in an applicable reporting period, but extenuating circumstances prevented them from doing so by the required deadline. PRF Period 2 (when payment was received) covered July 1, 2020, through December 31, 2020, with an associated reporting period (RP2) of January 1, 2022, to March 31, 2022. The deadline to request to report late for RP2 is Friday, May 13, 2022, at 11:59 p.m. ET.

April 26, 2022

The Association for Clinical Oncology (ASCO) is calling on Congress to continue their bipartisan support for cancer research. Robust, sustained, and predictable funding growth for the National Institutes of Health (NIH) and the National Cancer Institute (NCI) are vital in our nation’s efforts to combat and ultimately cure diseases like cancer.

April 12, 2022

From April 4-8, U.S. members of the Association for Clinical Oncology (ASCO) participated in the 2022 ASCO Week of Action, which was held in conjunction with the Association’s annual Advocacy Summit. During the Week of Action, advocates from across the country sent a record 920 letters to Members of Congress through ASCO’s ACT Network urging them to take action on important policies to improve access to high-quality, equitable care for people with cancer. During the Advocacy Summit 132 ASCO members from 43 states and the District of Columbia held nearly 200 virtual meetings with Members of Congress and staff to urge action on the same issues.

April 4, 2022

The Association for Clinical Oncology (ASCO) congratulates Dr. Norman E. “Ned” Sharpless on his successful tenure as Director of the National Cancer Institute (NCI). During his five years at NCI, Dr. Sharpless guided the Institute to advance the goals of the Cancer Moonshot Initiative, including important work to modernize cancer clinical trials to reflect an improved understanding of biology and the new types of therapies available to treat cancer. We are hopeful that these efforts will endure even after Dr. Sharpless’ departure later this month.

March 29, 2022

President Biden’s Fiscal Year (FY) 2023 budget request includes $5 billion for the Advanced Research Projects Agency for Health (ARPA-H), the proposed new biomedical research agency focused on high-risk, bold, translational research projects. While the Association for Clinical Oncology (ASCO) strongly believes in the stated mission of ARPA-H, we are concerned that the Administration’s FY 2023 budget request invests in ARPA-H at the expense of the National Institutes of Health (NIH) and the National Cancer Institute (NCI).

March 17, 2022

Congress is considering several cancer policy priorities this week, including the PREVENT Pandemics Act, Cures 2.0, and legislation to authorize ARPA-H.

March 17, 2022

On March 17, the American Society of Clinical Oncology (ASCO) is hosting a meeting with key research stakeholders to discuss possible solutions and calls-to-action to optimize cancer clinical trials and facilitate routine patient access to trials closer to where they live.

March 15, 2022

The Association for Clinical Oncology (ASCO) is holding its annual Advocacy Summit Week of Action from April 4-8, during which ASCO members are encouraged to connect with their Members of Congress about policies and legislation that impact cancer care and research.

March 11, 2022

The Fiscal Year 2022 omnibus funding bill provides $45 billion for the National Institutes of Health (NIH), including $6.9 billion for the NCI. The Association for Clinical Oncology (ASCO) commends Congress for their enthusiastic, bipartisan support for continued investment in biomedical research.